contact@asploro.com
Diabetes Research: Open Access

DROA

Diabetes Research: Open Access

About this Journal

Diabetes Research: Open Access is an Open Access Journal which releases Scholarly Articles featuring the content about Diabetes and Endocrinology.

The extent of the journal incorporates endocrine organs, hormonal discharges, hormonal receptors and the hormone controlled metabolic pathways. It also includes the clinical investigation of disorders related to Diabetes.

The articles including diabetes featured symptoms, causes, pathophysiology, conclusion,…

Submit manuscript as an e-mail attachment to the Editorial Office at diabresearch@clinicalsci.com or through online at Submit Manuscript

Special Issue

Special Issue Entitled: SGLT2 Inhibitor is being edited by

Dr. Serife M Kuskonmaz

Dr. Şerife Mehlika Kuşkonmaz

Ankara Training and Research Hospital, Department of Endocrinology and Metabolism

Email: mehlikaisildak@gmail.com

Diabetes treatment and side effects of antidiabetic medications, disorders of parathyroid, pituitary diseases.

Dr. Şerife Mehlika Kuşkonmaz was born in 1975 in Ankara. She was graduated from Hacettepe University Faculty of Medicine at 1999. She trained in Internal Medicine and in Endocrinology and Metabolism at Hacettepe University Hospital between 2000-2008. She worked in different medical centers as a specialist in the field of endocrinology, including Başkent University Hospital and Güven Hospital. Dr. Kuşkonmaz is now working as an associate professor in Ankara Research and Training Hospital Department of Endocrinology and Metabolism.

Why Publish With Us

  • All the published articles are open access which means it’s free to access from anywhere in the world.
  • Each case published in this journal can improve health outcomes.
  • We offer fast publication while providing rigorous peer review to maintain the integrity of information.
  • Each article will be published under a Creative Commons license and authors are the copyright holder.
  • We are committed to the highest standards of peer review.
  • We’re proud of the impact and influence this journal have – from citations to social media shares.
  • We’re committed to promoting your work as widely as we can and providing as much visibility and exposure for your article as possible.

Tweets

Latest Papers

Editorial

Diabetes is a worldwide health issue affecting about 415 million people at present and more and more sufferers are expected to be seen in near future. The physicians working in the field of diabetes certainly have to update their knowledge about the disease, its complications and managent strategies. Moreover physicians who are not directly involved in the follow up and management of diabetes-such as orthopedic surgeons, ophtalmologists, neurologists, cardiologists and doctors who deal with transplant medicine- will surely encounter diabetic patients in daily practice because of various aspects of the disease presentation.

Abstract

The world is facing a major epidemic of diabetes mellitus (DM) & available reports suggest that all these patients are at risk of developing diabetic foot ulcer (DFU). Approximately 50 – 60% of all DFUs can be classified as neuropathic. Signs or symptoms of vascular compromise are observed in 40 to 50% of all patients with the vast majority having neuro-ischemic ulcers, and only a minority of patients has purely ischemic ulcers. Diabetic foot infections are usually polymicrobial in nature, involving both aerobes and anaerobes, which can decay any part of the body especially the distal part of the lower leg. However, one of the hidden barriers to wound healing is the presence of biofilm in chronic DFUs. Biofilms are difficult to identify & diagnose, recalcitrant to topical antibiotics & can reoccur even after sharp debridement. More than 90% of chronic wounds are complicated with biofilms. Hence, early identification and management of diabetic foot infections becomes imperative in order to prevent complications & amputation. Debridement is considered to be the gold standard treatment approach for managing DFU manifested with necrotic tissue. However, biofilm can reform even after sharp debridement and can delay healing & recovery. Also, antibiotics & few antiseptics have limited role in managing DFUs complicated with biofilm. Until recently, Cadexomer iodine, a new generation iodine formulation with microbead technology has taken a different profile in wound care. It can effectively manage biofilm along with exudate & possesses superior desloughing action. Additionally, appropriate ways of offloading, dressings & use of newer treatment strategies like negative pressure wound therapy (NPWT), hyperbaric oxygen therapy (HBOT) and / or use of growth factors can ensure faster healing & early wound closure. Although, commendable efforts in recent years have been taken in the diagnosis and treatment of DFU, it still remains a major public health concern.

Diabetic Foot Infection, Biofilm & New Management Strategy
Diabetic Foot Infection, Biofilm & New Management Strategy
Diabetic Foot Infection, Biofilm & New Management Strategy

In this editorial, I would like to go through some philosophical aspects in conceptual formulations. Diabetes has been defined as part of metabolic syndrome. Diabetes is associated with insulin deficiency either in concentration or function. This is the classical and traditional picture associated with diabetes type 2. Diabetic complications are also associated with these concepts involving the metabolic points of view.

Congratulations on the inaugural issue of Diabetes Research: Open Access (DROA). Across the world, the necessity of medical practice and research concerning diabetes has been more emphasized. The significant role of this journal will be expected from now.

In recent years, lifestyle-related diseases such as obesity and diabetes have increased worldwide as non-communicable diseases (NCDs). Statistically, 71% of 57 million world deaths in 2016 were from NCDs. The United Nations meeting on NCSs reviewed the global progress for the prevention and control of NCDs, and proposed countdown 2030 for reduction of the burden of NCDs. Among NCDs, diabetes and hypertension have been prevalent and important to manage in the clinical practice.